{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:45:21Z","timestamp":1782924321509,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endoscopic lung volume reduction (ELVR) using endobronchial valves is an established treatment for advanced COPD and emphysema. To reduce procedure-related complications such as pneumonia or exacerbations, peri-interventional antibiotic prophylaxis is commonly used; however, its clinical benefit remains uncertain. We aimed to evaluate the effect of different peri-interventional antibiotic strategies in a German COPD cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Comparative analyses were performed using data from 900 patients enrolled in the multicentre, observational German Lung Emphysema Registry (LE-Registry). Patients were categorized by peri-interventional antibiotic strategy: single-dose prophylaxis, prolonged prophylaxis for 5\u20137\u00a0days, or no prophylaxis. Baseline characteristics, airway colonization, lung function, symptom burden, exercise capacity, and adverse events were assessed up to three months after ELVR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 900 patients undergoing ELVR, 104 received single-dose prophylaxis, 344 prolonged 5\u20137-day prophylaxis, and 309 no antibiotic prophylaxis. Clinical improvements in lung function, symptom burden, and exercise capacity over three months were similar across all groups. Exacerbations occurred in 11.5% of patients receiving single-dose prophylaxis (12\/104), 7.6% with prolonged prophylaxis (26\/344), and 5.5% without prophylaxis (17\/309;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.12). Pneumonia was observed in 7.7% (8\/104), 3.2% (11\/344), and 3.2% (10\/309), respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.087). Antibiotic-related adverse events were infrequent and mild, occurring only in the prolonged prophylaxis group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Peri-interventional antibiotic prophylaxis, whether single-dose or prolonged, did not improve clinical outcomes or reduce complication rates following ELVR. These findings indicate limited clinical benefit and support a more targeted, indication-based use of antibiotics in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-026-02742-w","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:27:55Z","timestamp":1771003675000},"page":"1279-1288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peri-interventional antibiotic prophylaxis in endoscopic valve implantation for lung volume reduction in COPD patients: results from a German multicenter observational cohort"],"prefix":"10.1007","volume":"54","author":[{"given":"Eva","family":"Pappe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadis","family":"Darvishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sgarbossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Saccomano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaid","family":"Darwiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Eisenmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Gesierich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Dickgreber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Geltner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim Hans","family":"Ficker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Schwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Eggeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Grah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"H\u00fcnermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urte","family":"Sommerwerck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Fertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylke","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinah","family":"von Sch\u00f6ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif Erik","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Witzenrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf-Harto","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the German Lung Emphysema Registry study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"6","key":"2742_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1159\/000496122","volume":"97","author":"FJF Herth","year":"2019","unstructured":"Herth FJF, et al. Endoscopic lung volume reduction: an expert panel recommendation - update 2019. Respiration. 2019;97(6):548\u201357.","journal-title":"Respiration"},{"issue":"9","key":"2742_CR2","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1164\/rccm.201803-0590OC","volume":"198","author":"GJ Criner","year":"2018","unstructured":"Criner GJ, et al. A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med. 2018;198(9):1151\u201364.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"2742_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1164\/rccm.201707-1327OC","volume":"196","author":"SV Kemp","year":"2017","unstructured":"Kemp SV, et al. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med. 2017;196(12):1535\u201343.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"2742_CR4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1164\/rccm.201607-1383OC","volume":"194","author":"A Valipour","year":"2016","unstructured":"Valipour A, et al. Endobronchial valve therapy in patients with homogeneous emphysema. results from the IMPACT study. Am J Respir Crit Care Med. 2016;194(9):1073\u201382.","journal-title":"Am J Respir Crit Care Med"},{"issue":"24","key":"2742_CR5","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMoa1507807","volume":"373","author":"K Klooster","year":"2015","unstructured":"Klooster K, et al. Endobronchial valves for emphysema without interlobar collateral ventilation. N Engl J Med. 2015;373(24):2325\u201335.","journal-title":"N Engl J Med"},{"issue":"9998","key":"2742_CR6","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S0140-6736(15)60001-0","volume":"386","author":"C Davey","year":"2015","unstructured":"Davey C, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial. Lancet. 2015;386(9998):1066\u201373.","journal-title":"Lancet"},{"issue":"13","key":"2742_CR7","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa0900928","volume":"363","author":"FC Sciurba","year":"2010","unstructured":"Sciurba FC, et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med. 2010;363(13):1233\u201344.","journal-title":"N Engl J Med"},{"issue":"5","key":"2742_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1159\/000506522","volume":"99","author":"RH H\u00fcbner","year":"2020","unstructured":"H\u00fcbner RH, et al. Endoscopic lung volume reduction: can endobronchial valves be safely removed? Respiration. 2020;99(5):459\u201360.","journal-title":"Respiration"},{"issue":"5","key":"2742_CR9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1159\/000494327","volume":"97","author":"S Li","year":"2019","unstructured":"Li S, et al. The REACH trial: a randomized controlled trial assessing the safety and effectiveness of the Spiration\u00ae valve system in the treatment of severe emphysema. Respiration. 2019;97(5):416\u201327.","journal-title":"Respiration"},{"key":"2742_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/COPD.S150705","volume":"13","author":"FC Trudzinski","year":"2018","unstructured":"Trudzinski FC, et al. Microbiological airway colonization in COPD patients with severe emphysema undergoing endoscopic lung volume reduction. Int J Chron Obstruct Pulmon Dis. 2018;13:29\u201335.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2742_CR11","unstructured":"S3-Leitlinie Perioperative und Periinterventionelle Antibiotikaprophylaxe \u2013 Aktualisierung 2024. Langversion, 5.0. 2024. AWMF Registernummer: 067\/009, https:\/\/register.awmf.org\/de\/leitlinien\/detail\/067-009"},{"key":"2742_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"issue":"4","key":"2742_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000542806","volume":"104","author":"T Sgarbossa","year":"2025","unstructured":"Sgarbossa T, et al. Comparison of efficacy and safety of different types of one-way valves in endoscopic lung volume reduction in patients with severe lung emphysema. Respiration. 2025;104(4):281\u20139.","journal-title":"Respiration"},{"key":"2742_CR14","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00410-2024","author":"J Saccomanno","year":"2025","unstructured":"Saccomanno J, et al. Clinical improvements after endoscopic lung volume reduction with valves in patients with advanced emphysema and a 6-min walk test \u2264140\u2005m at baseline. ERJ Open Res. 2025. https:\/\/doi.org\/10.1183\/23120541.00410-2024.","journal-title":"ERJ Open Res"},{"key":"2742_CR15","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00190-2023","author":"T Sgarbossa","year":"2023","unstructured":"Sgarbossa T, et al. Assessment of efficacy and safety of endoscopic lung volume reduction with one-way valves in patients with a very low FEV(1). ERJ Open Res. 2023. https:\/\/doi.org\/10.1183\/23120541.00190-2023.","journal-title":"ERJ Open Res"},{"issue":"3","key":"2742_CR16","first-page":"211","volume":"10","author":"E Pappe","year":"2023","unstructured":"Pappe E, et al. Impact of coronavirus disease 2019 on hospital admissions, health status, and behavioral changes of patients with COPD. Chron Obstr Pulm Dis. 2023;10(3):211\u201323.","journal-title":"Chron Obstr Pulm Dis"},{"issue":"9","key":"2742_CR17","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1159\/000524996","volume":"101","author":"P Lenga","year":"2022","unstructured":"Lenga P, et al. Endoscopic lung volume reduction with one-way valves in patients with severe chronic obstructive pulmonary disease with hypercapnia. Respiration. 2022;101(9):823\u201332.","journal-title":"Respiration"},{"key":"2742_CR18","doi-asserted-by":"crossref","unstructured":"Lenga P., et al. Endoscopic lung volume reduction with endobronchial valves in very low D (LCO) patients: results from the German Registry - Lungenemphysemregister e.V. ERJ Open Res, 2021. 7(1).","DOI":"10.1183\/23120541.00449-2020"},{"key":"2742_CR19","unstructured":"Mikrobiologisch-infektiologische Qualit\u00e4tsstandards : MiQ ; Qualit\u00e4tsstandards in der mikrobiologisch-infektiologischen Diagnostik \/ Expertengremium Mikrobiologische-Infektiologische Qualit\u00e4tsstandards (MiQ) ; Qualit\u00e4tssicherungskommission der Deutschen Gesellschaft f\u00fcr Hygiene und Mikrobiologie (DGHM). Im Auftr. der Deutschen Gesellschaft f\u00fcr Hygiene und Mikrobiologie (DGHM). M\u00fcnchen: Elsevier, Urban & Fischer."},{"issue":"1","key":"2742_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.mayocpiqo.2020.09.009","volume":"5","author":"KM Nada","year":"2021","unstructured":"Nada KM, Nishi S. Endoscopic lung volume reduction: review of the EMPROVE and LIBERATE trials. Mayo Clin Proc Innov Qual Outcomes. 2021;5(1):177\u201386.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"11","key":"2742_CR21","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1164\/rccm.201902-0383OC","volume":"200","author":"GJ Criner","year":"2019","unstructured":"Criner GJ, et al. Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). a multicenter, open-label randomized controlled clinical trial. Am J Respir Crit Care Med. 2019;200(11):1354\u201362.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2742_CR22","doi-asserted-by":"publisher","first-page":"23078","DOI":"10.1038\/s41598-024-73950-3","volume":"14","author":"E Pappe","year":"2024","unstructured":"Pappe E, et al. Biofilm infections of endobronchial valves in COPD patients after endoscopic lung volume reduction: a pilot study with FISHseq. Sci Rep. 2024;14(1):23078.","journal-title":"Sci Rep"},{"issue":"1","key":"2742_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/crj.13450","volume":"16","author":"D Abia-Trujillo","year":"2022","unstructured":"Abia-Trujillo D, et al. Prevention of acute exacerbation of chronic obstructive pulmonary disease after bronchoscopic lung volume reduction with endobronchial valves. Clin Respir J. 2022;16(1):43\u20138.","journal-title":"Clin Respir J"},{"key":"2742_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/COPD.S148196","volume":"13","author":"N Sarmand","year":"2018","unstructured":"Sarmand N, et al. New bacterial growth in bronchial secretions after bronchoscopic valve implantation. Int J Chron Obstruct Pulmon Dis. 2018;13:565\u201370.","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02742-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02742-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02742-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:49:48Z","timestamp":1782920988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02742-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2742"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02742-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8280597\/v1","asserted-by":"object"}]},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.P.:\n                      No conflict of interest.\n                      H.D.:\n                      No conflict of interest.\n                      T.S.:\n                      No conflict of interest.\n                      J.S.:\n                      received payment or support for attending congresses from PulmonX and Boehringer Ingelheim, serves on the scientific advisory board of LE-Registry.\n                      K.D.:\n                      received payment or honoraria for lectures and consulting, from bess, Lys Medical, Olympus, PulmonX, Boston Scientific, Boehringer Ingelheim, Broncus Medical, Erbe, Storz, Fujifilm, Intuitive, payments to the institution from Boston Scientific, Boehringer Ingelheim, Broncus Medical, Erbe, Lys Medical, Olympus, PulmonX, Storz, participates on the societies: DGP, and World Association for Bronchology and Interventional Pneumology.\n                      S.A.:\n                      received payment or honoraria for lectures and consulting, from Sanofi, Boehringer Ingelheim, Novartis, AstraZeneca, GSK, Chiesi, Merini, support for attending congresses from Boehringer Ingelheim, speaker of the Section \u201cTabakentw\u00f6hnung\u201d at DGP and board member of the ABNR.\n                      S.E.:\n                      received payment or honoraria for lectures from PulmonX.\n                      B.S.:\n                      No conflict of interest.\n                      W.G.:\n                      received payment or honoraria for lectures from Astra Zeneca, Boehringer Ingelheim, Bristol Myers Sqibb, PulmonX, Springer Medicine\n                      N.D.:\n                      No conflict of interest.\n                      C.G.:\n                      No conflict of interest.\n                      J.F.:\n                      No conflict of interest.\n                      A.H.:\n                      No conflict of interest.\n                      B.S.:\n                      No conflict of interest.\n                      S.E.:\n                      serves on the scientific advisory board of LE-Registry.\n                      R.E.:\n                      received payment or honoraria for lectures from AstraZeneca, CSL Behring, Olympus, Pulmonx, Pentax, serves on the scientific advisory board of LE-Registry.\n                      C.G.:\n                      No conflict of interest.\n                      C.H.:\n                      No conflict of interest.\n                      U.S.:\n                      No conflict of interest.\n                      A.F.:\n                      No conflict of interest.\n                      S.K.:\n                      No conflict of interest.\n                      P.S.:\n                      No conflict of interest.\n                      D.S.:\n                      No conflict of interest.\n                      L.E.S.:\n                      No conflict of interest.\n                      M.W.:\n                      received grants from Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt (BMFTR; Federal Ministry of Research, Technology and Space), Deutsche Forschungsgemeinschaft (DFG; German Research Foundation), Gemeinsamer Bundesausschuss (G-BA; The Federal Joint Committee), Bundesministerium f\u00fcr Gesundheit (BMG; Federal Ministry of Health), received payment or honoraria for lectures and consulting from Biotest, Pantherna, Aptarion, Biotest, Pantherna, Aptarion, Astra Zeneca, Chiesi, Insmed, Gilead, Pfizer, Boehringer Personal Fees\n                      R-H.H.:\n                      received study fee (Convert) from Pulmonx; received payment or honoraria for lectures from Berlin Chemie, Astra, Chiesi and Pulmonx; an received payment or support for attending congresses Medtronic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}